Drug Trial Radar · NCT02454712
Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Nov 16, 2016
Primary completion
Jan 18, 2018
Study completion Jan 18, 2018
Sponsor
- Lead sponsor
- Ensysce BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- PRA Health Sciences
- First posted
- May 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
PF614 is an oxycodone prodrug that is designed for extended-release of oxycodone comparable to OxyContin. This Single Ascending Dose (SAD) study is designed to assess the safety and pharmacokinetics (PK) of PF614 in comparison to standard doses of OxyContin.
Conditions
- Healthy
Interventions
PF614Drug
PF614 is an oxycodone prodrug
Oxycodone extended-releaseDrug
Oxycodone extended-release is the comparator drug
Naltrexone HydrochlorideDrug
Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRA Health Sciences - Early Development Services
Lenexa, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.